About Myriad Genetics
What Myriad Genetics is building
Technologies used at Myriad Genetics
Javascript
HTML
CSS
ReactFunding rounds
Company type
Myriad Genetics news and updates
Myriad Genetics hired Glenn Farrell as SVP and CMO on Nov 20th 22'.
Glenn Farrell recently joined Myriad as SVP and CMO, he has more than 25 years of experience leading brand strategy and successful go-to-market programs in healthcare, life sciences and technology and most recently served as the CMO and founding team member at Sema4 Holdings.
Dec 19, 2022 | seekingalpha.comMyriad Genetics hired Marc Leighton as Senior Vice President (SVP) for Product Management on Nov 19th 22'.
Marc Leighton recently joined Myriad as Senior Vice President (SVP) for Product Management.
Dec 18, 2022 | myriad.comMyriad Genetics partners with DNAnexus Inc.
Myriad Genetics is collaborating with partners such as Illumina, Intermountain Healthcare, AstraZeneca, MSD and DNANexus, to name a few.
Sep 26, 2022 | myriad.comMyriad Genetics partners with N.C. Central University
Myriad Genetics partnered with North Carolina Central University, a historically black university based in Durham, N.C. Four exceptional interns were selected to participate in its inaugural internship program designed for diverse students in science at Historically Black Colleges & Universities.
Aug 25, 2022 | myriad.comMyriad Genetics launched MyRisk hereditary cancer test on Feb 24th 21'.
Last year, Myriad also launched its MyRisk hereditary cancer test with a polygenic breast cancer risk test, called RiskScore, calibrated for women of all ancestries.
Jan 1, 2022 | genomeweb.comMyriad Genetics recognized as one of the World’s Most Innovative Companies on Mar 1st 22'.
In March 2022, Myriad Genetics was named one of the World’s Most Innovative Companies by Fast Company.
Jan 1, 2022 | myriad.comMyriad Genetics launches Precise Oncology Solutions
Myriad Genetics announced the launch of Precise Oncology Solutions, a new service through which oncologists can order its BRACAnalysis CDx and MyChoice CDx; its MyRisk Hereditary Cancer Test; and the Precise Tumor Molecular Profile Test, which is performed at a CLIA-certified lab operated by Intermountain Healthcare.
Jan 1, 2022 | genomeweb.comMyriad Genetics hired Lanchbury on Sep 1st 02'.
Lanchbury joined Myriad Genetics in September 2002.
Jan 1, 2022 | myriad.comJeff left Myriad Genetics as Chief Marketing Officer on Feb 28th 22'.
Jeff joins Immunovia from Myriad Genetics, a leader in genetic testing and precision medicine, where he most recently served as Chief Marketing Officer.
Jan 1, 2022 | biospace.comMyriad Genetics launches analysis of GeneSight Psychotropic
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis of GeneSight ® Psychotropic, the company’s mental health medication test, in its Feb. 2022 edition.
Jan 1, 2022 | myriad.comMyriad Genetics launched Vectra Cardiovascular Risk assessment software on Feb 1st 21'.
For instance, in February 2021, Myriad Genetics Inc., a well-known vendor of genetic testing as well as precision medicine, introduced its latest Vectra Cardiovascular Risk assessment software that predicts the chances of cardiovascular events in those suffering from rheumatoid arthritis.
Jan 1, 2022 | digitaljournal.comMyriad Genetics hires Jones Day
Myriad hired Jones Day, one of the nation’s largest and most formidable law firms.
Jan 1, 2022 | facingourrisk.orgMyriad Genetics partnered with Epic Systems on Jun 23rd 22'.
Myriad Genetics on Thursday said that through a partnership with Epic Systems doctors will be able to order its genetic tests and view patients' results directly within the electronic medical records platform hosted by the software company.
Jan 1, 2022 | genomeweb.comMyriad Genetics launched version of market-leading MyRisk Hereditary Cancer Test with RiskScore on Jan 1st 21'.
In 2021, Myriad launched the newest version of its market-leading MyRisk™ Hereditary Cancer Test with RiskScore® which, for the first time offers women of all ancestries a personalized polygenic breast cancer risk assessment.
Jan 1, 2022 | myriad.comMyriad Genetics partnered with Intermountain on Mar 2nd 21'.
Myriad Genetics on Tuesday said it will combine its hereditary cancer risk tests and companion diagnostics in a single offering with tumor tissue profiling services offered through Intermountain Healthcare's Intermountain Precision Genomics service.
Mar 2, 2021 | genomeweb.comCharles Schwab Investment Management, Inc. invests into Myriad Genetics
The California-based Charles Schwab Investment has invested 0.02% in Myriad Genetics, Inc. (NASDAQ:MYGN).
Jan 1, 2019 | investtribune.com